Market Place
Sourcing Support
All News #Library
Biotech
Preliminary Results for the Year Ended 31 December 2025
27 Mar 2026 //
GLOBENEWSWIRE
Biodexa Launches Global Early Access Program for eRapa in FAP
23 Mar 2026 //
GLOBENEWSWIRE
ADR Ratio Adjustment Takes Effect
18 Mar 2026 //
GLOBENEWSWIRE
Biodexa Backs `Life`s a Polyp,` First U.S. FAP Group
09 Mar 2026 //
GLOBENEWSWIRE
Biodexa Announces Exclusive License of Otsuka’s OPB-171775
06 Feb 2026 //
GLOBENEWSWIRE
Biodexa Initiates First European Site For Phase 3 Serenta Trial
24 Nov 2025 //
GLOBENEWSWIRE
Biodexa Gets Europe CTA Approval For Phase 3 Serenta Trial
03 Nov 2025 //
GLOBENEWSWIRE
Biodexa Hosts FAP Mechanisms Symposium At CGA – IGC Conference
06 Oct 2025 //
GLOBENEWSWIRE
Biodexa`s Race to Launch Phase 3 FAP Program for $7Bn Market Lead
28 Jul 2025 //
ACCESSWIRE
Biodexa Enrolls First Patient in Phase 2a Study for Tolimidone
18 Jun 2025 //
ACCESSWIRE
Biodexa Reports Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma
08 Feb 2024 //
GLOBENEWSWIRE
Biodexa Completes Recruitment of Cohort A in Study of MTX110
03 Oct 2023 //
GLOBENEWSWIRE
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110
21 Sep 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.